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Context Vitamin D has several effects on the immune system that might be of relevance for 
the pathogenesis of type 1 diabetes (T1D). 
Objective To evaluate whether umbilical cord serum concentrations of 25-hydroxy-vitamin 
D (25[OH]D) differ in children developing either islet autoimmunity (IA) or overt T1D 
during childhood and adolescence.  
Design Umbilical cord serum samples from 764 children born 1994-2004 with HLA-DQB1 
conferred risk for type 1 diabetes (T1D) participating in the Type 1 Diabetes Prediction and 
Prevention Study (DIPP) were analyzed for 25(OH)D using an enzyme immunoassay.  
Setting DIPP clinics in Turku, Oulu, and Tampere University Hospitals, Finland. 
The participants comprised 250 case children who developed T1D diabetes at a median age 
of 6.7 years (interquartile range [IQR] 4.0-10.1 years) and 132 additional case children who 
developed IA, i.e. positivity for multiple islet autoantibodies. Cases were matched for date of 
birth, sex and area of birth with 382 control children who remained autoantibody negative. 
The median duration of follow-up was 9.8 years (IQR 5.7-13.1 years).  
Main Outcome Measure The median 25(OH)D concentrations  
Results The median 25(OH)D concentration in cord serum was low (31.1 nmol/L [IQR 24.0-
41.8]; 88% < 50 nmol/L), but not statistically different between children who developed T1D 
or IA and their control groups (P=0.70). The levels were associated mainly with geographical 
location, year and month of birth, age of the mother and maternal intake of vitamin D during 
pregnancy.    
Conclusions The 25(OH)D concentrations at birth are not associated with the development of 
T1D during childhood.  
Umbilical cord serum samples were measured for 25[OH]D in 382 case children developing either 
islet autoimmunity or T1D, and in 382 matched controls. The levels were low and not associated with 
T1D. 
Abbreviations  
25(OH)D, 25-hydroxyvitamin D; DIPP, Type 1 Diabetes Prediction and Prevention study; GADA, 
glutamic acid decarboxylase autoantibody; HLA, human leukocyte antigen; IA, islet autoimmunity; 
IAA, insulin autoantibody; IA-2A, autoantibody against the tyrosine phosphatase-related IA-2 protein;  
ICA, islet cell antibody; IQR, interquartile range; SNP, single nucleotide polymorphism; T1D, type 1 
diabetes 
Introduction 
Vitamin D is one of the essential players in metabolic and physiological processes in the 
human body. It has multiple effects on the immune system, and its role in the pathogenesis of 
immune-mediated diseases has long been suspected. We noticed an increase in 25-
hydroxyvitamin D (25[OH]D) concentrations in Finnish children after year 2003, when 
vitamin D fortification of milk started in Finland, which preceded the plateauing of the rapid 
increase in type 1 diabetes (T1D) incidence that had continued for more than 50 years (1). 
However, we found no difference in median 25(OH)D concentration between children who 
developed T1D and  healthy matched control children when the children were observed from 
the age of three months until the diagnosis of T1D (2).  
T1D is an immune-mediated disease, which can manifest at any age (3). Diagnosis in 
early childhood, before the age of four years, is quite common especially in Finland, where 
the incidence is highest in the world (4) and some children develop T1D even before the age 
of one year (5). The factors initiating or triggering the immune-mediated process leading to 
the disease must be operative before that, perhaps already during fetal life. Some changes can 
be seen early on and we have detected differences in the lipidomic profile in cord serum 
samples in children  who later progressed rapidly to T1D, but not in those developing islet 
autoimmunity (IA) without progressing to overt disease (6).  
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Here we assessed the possible association of fetal vitamin D levels and the development 
of IA and progression to clinical T1D by measuring umbilical cord serum 25(OH)D 
concentration in the DIPP birth cohort study. Further, we analyzed maternal intake of vitamin 
D during pregnancy in a subcohort.    
Materials and Methods  
The study population comprised children (born 1994-2004), who participated in the Type 1 
Diabetes Prediction and Prevention Study (DIPP) in Finland. The DIPP project is an ongoing 
population-based prospective birth cohort study aimed at exploring means to predict and 
prevent progression to clinical type 1 diabetes (T1D) (7). Briefly, newborn infants with HLA-
DQB1-conferred susceptibility to T1D are recruited from the University Hospitals in Turku 
(60 °N), Oulu (65 °N), and Tampere (61 °N), Finland. The children attend the study centers 
for follow-up visits at three to 12 month intervals and their serum samples are analyzed for 
T1D-related autoantibodies. Islet cell antibodies (ICA) were used as the primary screening 
tool for β-cell autoimmunity. If a child seroconverted to positivity for ICA, all the preceding 
and subsequent samples of this child were analyzed for insulin autoantibodies (IAA), 
antibodies to the 65 kDa isoform of glutamic acid decarboxylase (GADA) and to the tyrosine 
phosphatase-related islet antigen 2 (IA-2A). Data from the autoantibody negative children 
participating in the follow-up were collected until they were 15 years of age, or until the end-
point of this study (July 2016). Data from the autoantibody positive children were collected 
until the follow-up for this study ended, or until they were diagnosed with T1D according to 
the World Health Organization criteria, whichever came first. 
We analyzed the concentration of 25-hydroxyvitamin D (25[OH]D) in umbilical cord 
serum samples from 764 DIPP study participants with a nested case-control design. There 
were 133 case-control pairs in the Turku cohort, 137 in the Oulu cohort and 112 in the 
Tampere cohort. Case children comprised two groups; the majority of the cases (250 
children) were diagnosed with T1D by the end of July 2016 (T1D+) and the minority of cases 
(132 children) showed IA testing positive for multiple (≥2) autoantibodies, but not 
progressing to overt T1D by the end of the study period (IA+). The cases were included 
based on the availability of samples and one control subject was selected for each case child. 
All control subjects (T1D- and IA-) remained autoantibody-negative and non-diabetic 
throughout the follow-up, and they were pairwise matched for age (birth within 30 days), sex 
and study center.  
Mixed arterial/venous umbilical cord blood was collected in the delivery room and these 
samples were used for both serum extraction and genetic screening. Serum samples were 
stored at -70 ºC. All children were initially screened for HLA-DQB1 alleles (8). An extended 
six-scale HLA-DR/DQ genotype-based T1D risk classification (9) was available in 625 of the 
764 children. The three groups with decreased or neutral risk were combined into a “non-
increased risk” group, as the number of children in these groups was small. One child (IA+) 
carried a genotype conferring strongly decreased risk, six children (two IA-, and four T1D-) 
had genotypes conferring slightly decreased risk and 28 children (seven IA+, 10 IA-, two 
T1D+, and nine T1D-) carried genotypes conferring neutral risk, so that the non-increased 
risk group included 35 children, while there were 135 children (30 IA+, 28 IA-, 33 T1D+, 
and 44 T1D-) with slightly increased risk, 279 children (71 IA+, 29 IA-, 125 T1D+, and 54 
T1D-) with moderately increased risk, and 176 children (23 IA+, 16 IA-, 89 T1D+, and 48 
T1D-) with genotypes conferring highly increased risk for T1D.  
We were able to obtain maternal dietary data collected by a validated food frequency 
questionnaire after the birth of the child. The mothers were asked for food consumption 
during one month preceding the pregnancy leave i.e. the eighth month of pregnancy. Total 
energy intake and vitamin D intake from food, supplements, and in total were used in the 
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current study, as described by Marjamäki et al. (10), from the mothers of 363 children in this 
study (63 IA+, 60 IA-, 121 T1D+ and 119 T1D-); 168 in the Oulu and 195 in the Tampere 
cohorts.  
A commercial immunoassay kit (Immunodiagnostic Systems Ltd, Boldon, UK) was used 
for the 25(OH)D analyses, as previously described (1). The intra-assay coefficient of 
variation was 6.5% and the sensitivity was 5 nmol/L. The performance target set by the 
Vitamin D External Quality Assessment Scheme Advisory Panel for 25(OH)D assays was 
met (11).  
Statistical analyses were performed with JMP Pro 12.0.1 and SAS for Windows version 
9.4 (SAS Institute, Cary, NC, USA) using multi-way analysis of variance and Fisher’s exact 
test for categorical variables. Season of birth and study center were used as adjusting factors 
in all analysis. The value of P < 0.05 (two-tailed) was taken to indicate statistical 
significance. The year was divided into seasons as in our previous studies (1,2), i.e. winter 
(Jan-Mar), spring (Apr-Jun), summer (Jul-Sep) and fall (Oct-Dec). The 25(OH)D 
concentrations, energy intake and vitamin D intake from food, supplements and in total, were 
log-transformed responses in analyses requiring normal distribution. As zero values cannot be 
log transformed, 0.1 µg was added to vitamin D intake values from supplements to enable the 
log transformation and analysis. Possible confounding factors were controlled for by adding 
background variables to the statistical models as described in the Results section.  
The present study was conducted according to the guidelines of the Declaration of 
Helsinki, and was approved by the Joint Commission on Ethics of Turku University and 
Turku University Central Hospital. Written informed consent was obtained from all guardians 
of the subjects. 
Results 
Altogether, the study cohort included 382 case (250 T1D+, 132 IA+) and 382 control (250 
T1D-, 132 IA-) children, who were matched for age, sex and study center, as described in 
Subjects and methods. Serum 25(OH)D concentrations were statistically significantly 
affected by month of birth (Fig. 1) (P=0.002) and study center (P=0.03), so that the children 
of the Oulu center (65°N) had significantly lower levels than the children in Turku (60°N)  
and Tampere (61°N) centers, but not by sex (P=0.64). As dates of birth of cases and their 
controls were matched within one month, the age difference between them was small, the 
median being 6.5 days (IQR 2-13 days) for T1D+ and T1D-, and 6 days (IQR 3-15) for IA+ 
and IA- participants. The children were born rather evenly around the year. There were 210 
children born in the winter (62 T1D+, 63 T1D-, 44 IA+ and 41 IA-), 182 children born in the 
spring (64 T1D+, 61 T1D-, 28 IA+ and 29 IA-), 187 born in the summer (59 T1D+, 62 T1D-, 
33 IA+ and 33 IA-), and 185 born in the fall (65 T1D+, 64 T1D-, 27 IA+ and 29 IA-). 
The basic characteristics were similar between the study groups T1D+, T1D-, IA+ and 
IA- (Table 1). As expected (12), the T1D+ children seroconverted to autoantibody positivity 
at an earlier age than IA+ children, and the follow-up time was shorter in the T1D+ group 
due to the design of the study.  
Most importantly, there were no statistically significant differences in the median 
25(OH)D concentrations in cord serum between the study groups (P=0.70). The 25(OH)D 
concentrations of 675 cord serum samples were below 50 nmol/L and thus 88 % of the study 
children had suboptimal (13) vitamin D levels. When months were combined to seasons of 
birth, its significance on 25(OH)D concentrations increased (from P=0.002 to P<0.0001), 
with a  peak concentration during the summer months (Fig. 1).  
The association between 25(OH)D concentrations and group differences (T1D+, T1D-, 
IA+, IA-) was studied with multi-way analysis of variance (ANOVA). Also, these analyses 
were adjusted by season and study center. All interactions between the independent 
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explanatory variables were evaluated and if they were non-significant they were removed 
from the final model. In addition, the effect of year of birth, HLA-DQB1 group, HLA-
DR/DQ group, number of antibodies, ponderal index and nutritional factors with 25(OH)D 
concentration were evaluated in separate models with the analysis method explained above. 
Differences between the groups were non-significant in all the models reported below.  
The median age at the diagnosis of T1D was 6.7 years (IQR 4.0-10.9 years). The median 
age at seroconversion to autoantibody positivity in the T1D+ group was 2.0 years (IQR 1.1-
4.0) (N=235, information was not available for 15 subjects) and 4.0 years (IQR 1.8-6.2) in 
the IA+ group (N=132). The 25(OH)D concentrations were not associated with the age at 
T1D diagnosis (P=0.53) nor with the age of seroconversion to autoantibody positivity 
(P=0.72).  
During the follow-up there were 146 T1D+ and 31 IA+ children who tested positive for 
all four autoantibodies, 64 T1D+ and 45 IA+ children positive for three autoantibodies, 22 
T1D+ and 56 tested maximally positive for two autoantibodies, and additional six T1D+ 
children tested positive for the maximum of one autoantibody in their sample series, and 12 
T1D+ children had unknown autoantibody status (i.e. incomplete set of samples available for 
antibody analysis) before the diagnosis of T1D.  There were no statistically significant 
differences in 25(OH)D concentrations between these autoantibody groups (P=0.38). The 
situation was very similar when only biochemical autoantibodies were considered as were the 
numbers of children involved; there were 146 T1D+ and 31 IA+ children with three 
biochemical autoantibodies, 65 T1D+ and 46 IA+ with two, 24 T1D+ and 55 IA+ children 
with one, and three T1D+ children with only ICA, i.e. zero biochemical autoantibodies, all 
having similar 25(OH)D concentrations (P=0.32).  
There were 11 IA+ and 86 T1D+ children with IAA as the first appearing persistent 
biochemical autoantibody. No differences were found in 25(OH)D concentrations (P=0.61) 
between the groups of cases and their matched 97 controls in this subcohort. Similar results 
were obtained in the 70 IA+ and 39 T1D+ children in whom GADA was the first appearing 
persistent autoantibody; no differences were seen between the cases and their 109 controls 
(P=0.51).  
HLA-DQB1 group (moderate risk, high risk) was not associated 25(OH)D concentrations 
(P=0.57), neither were the extended HLA-groups (non-increased risk, slightly increased risk, 
moderately increased risk, and highly increased risk in HLA-DR/DQ) (P=0.46).  
The age of the mother at the time of birth was positively associated with 25(OH)D 
concentration (P=0.002) cord serum with higher concentration in older mothers. The median 
age of the mother was 29.8 (IQR 26.6-33.6) years, and it was highest in Turku (30.2 [IQR 
26.6-33.7] years) and lowest in Oulu (29.4 [26.3-33.0] years). The ponderal index of the 
child, calculated as weight in kg per height3, was inversely associated with 25(OH)D 
concentrations (P=0.031), but there was no statistically significant association with either 
weight  (P=0.29) or length (P=0.75) alone to 25(OH)D. The ponderal index did not correlate 
with the age of the mother (P=0.16).  
Almost 10% of the mothers had been smoking during pregnancy (70 smoking, 655 non-
smoking, 39 not known). There were mothers who had smoked in all groups: 20 were 
mothers to T1D+ children, 26 to T1D- children, nine to IA+ children and 15 to IA- children.  
Maternal smoking (yes/no) during pregnancy was not associated with 25(OH)D concentration 
in cord serum (P=0.40) and neither was the mode of delivery when all modes (vaginal 
delivery, emergency C-section, planned C-section, or assisted delivery) were taken into 
account. (P=0.17).   
As some have found cord serum 25(OH)D concentration quartiles to be an important 
factor in relation to T1D odds (14), we decided to analyze those as well. However, when we 
divided the samples into quartiles based on the 25(OH)D concentration (Table 2), the overall 
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difference between the groups (T1D+, T1D-, IA+ and IA-) remained statistically non-
significant (P=0.29), whereas study center and season remained statistically significant 
(P=0.003 and P<0.001, respectively).  
Nutrition during pregnancy 
We were able to obtain nutritional information from the eighth month of pregnancy in almost 
half (48%) of the study population, as 61% of the Oulu and 87% of the Tampere cohorts 
participated in the DIPP Nutrition Study. The general characteristics of the subpopulation in 
whom nutritional information was available are presented in Table 3.  
Maternal intake of vitamin D during pregnancy showed a statistically significant 
association with umbilical cord serum 25(OH)D concentrations in all forms, from food 
(P<0.0001), from supplements (P<0.0001), and in total (P<0.0001). The energy intake was 
not associated with 25(OH)D concentration (P=0.27). 
The age of the mother had a statistically significant association with 25(OH)D 
concentration also in this subpopulation (P=0.025), but age did not correlate with energy 
intake (P=0.64), vitamin D intake from food (P=0.22), intake from supplements (P=0.51), 
nor with total vitamin D intake (P=0.22). The median age of mothers was in the same range 
(29.3 years [IQR 26.4-33.4]) in this subpopulation as it was in the entire study cohort (29.8 
years [IQR 26.6-33.6]).    
Ponderal index of the baby was not associated with the 25(OH) concentration in this 
subpopulation (P=0.097) but its correlation with the age of the mother was close to 
significant (P=0.059). Ponderal index did not correlate with energy intake (P=0.34), vitamin 
D intake from food (P=0.30), from supplements (P=0.52), nor with total vitamin D intake 
(P=0.93) of the mother during pregnancy.  
When divided into the same quartiles based on 25(OH)D quarters as the entire data set 
(Table 4), there were no statistically significant differences in the proportion of children 
participating, or in energy intake in each quartile, but there were differences in vitamin D 
intake from food (P<0.001), from supplements (P<0.001) and in total  (P<0.001). 
The total vitamin D intake during pregnancy was quite low, as there were only 72 
children (20%) in this cohort whose mothers reported a total vitamin D intake during 
pregnancy ≥ 10 µg per day; 22 T1D+, 29 T1D-, 14 IA+ and 7 IA-. The median 25(OH)D 
concentration in these 72 serum samples was 39.1 (IQR 30.1-46.6) nmol/L.    
The use of vitamin D supplementation during pregnancy was uncommon, with only 33 
mothers (9%) getting  ≥ 5 µg vitamin D from supplements.; 10 T1D+, 13 T1D-, 6 IA+ and 4 
IA-. The supplement use was equally distributed between seasons; nine in winter, seven in 
spring, nine in summer and eight in fall. As the nutritional information was based on the 
eighth month of pregnancy, the season was mostly the same as the season of birth.  
Discussion 
Based on this study, fetal vitamin D status, reflected by umbilical cord serum 25(OH)D (15–
17), does not appear to have an association with islet autoimmunity or with progression to 
T1D. The 25(OH)D concentrations of the pregnant mothers are significantly lower than in the 
children in the upcoming months and years (2). The levels in cord serum or plasma seemed to 
be low worldwide (18,19) up until recently (17). 
Vitamin D supplementation is recommended for the whole growth period for all children 
in Finland and the parents comply well with this recommendation, at least for the first few 
years of life (20). The conspicuous monthly variation and the overall low 25(OH)D 
concentrations alone suggest that the pregnant women have not been taking commonly 
vitamin D supplementation, and this was confirmed by the nutritional data available. 
Similarly, in an earlier study of 1669 mothers from the same population cohort in Tampere 
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and Oulu, the mean maternal intake of vitamin D was 5.1 (SD 2.6) µg from food and 1.4 (SD 
2.6) µg from supplements, with only 32% of women taking vitamin D supplements during 
approximately the same study period, i.e. years 1997-2001 (21). It is noteworthy that we 
found no seasonal variation in vitamin D supplement usage, even though the 
recommendations advised pregnant women to use supplements only during the winter months 
(22–24). Thus, it seems that most Finnish mothers did not take care of their own vitamin D 
supplementation during pregnancy at the time, but were very careful in supplementation of 
their children. 
The major strength of the current study is that it includes a large number of children in 
matched case-control pairs and there is abundant follow-up data on these children. Collecting 
samples for over a decade is not an easy task to accomplish but it helps minimize annual 
fluctuations.  
Some study limitations should also be considered. One is that the children were originally 
selected for the DIPP study based on their HLA-DQB1 genotype and we did not have any 
genetic information on the mothers. No association of HLA-DRB1 or HLA-DQB1 with 
25(OH)D concentrations has been reported to the best of our knowledge, but an association 
of cord serum 25(OH)D concentrations and maternal  HLA-B44 (25) and two single 
nucleotide polymorphisms (SNPs), one for the vitamin D receptor gene and one for the 
group-specific component gene (26), have been observed in Finnish studies. Furthermore, we 
did not have SNPs of the vitamin D pathway in the children, which might have been 
interesting to have, as some of us, participating  in a large international collaboration study, 
found that 25(OH)D levels and vitamin D receptor polymorphism may have a combined role 
in the development of islet autoimmunity in children at increased genetic risk for T1D (27).   
It is noteworthy that the case children in this study were born evenly around the year in 
both case groups, those who developed T1D and those remaining autoantibody positive. This 
alone should indicate that the 25(OH)D concentration at birth may not be as important in the 
development of T1D as previously suggested (14). In an updated analysis of the same 
individuals of that previous Norwegian study, no association between first and second 
trimester 25(OH)D concentrations and childhood risk of T1D was observed (28). By 
analyzing neonatal blood spots, a small Italian study found no association between 25(OH)D 
levels and risk of T1D, except in a subgroup of migrant babies (29). A Danish research group 
showed with a larger cohort that that neonatal 25(OH)D status was not associated with a later 
risk of T1D (30). We were able to verify those results and went further, as we showed for the 
first time that 25(OH)D levels at birth were not associated with the progression to clinical 
T1D, the number of islet autoantibodies, nor with which autoantibodies appear first. 
This and the other studies where no differences regarding later risk of T1D was observed, 
(10,11) had very low median 25(OH)D levels. It might be possible that a difference could be 
detected in a more vitamin D sufficient population. However, in another autoimmune disease, 
multiple sclerosis, it was the lower spectrum of levels where the risk of the disease was most 
prominent (12). Accordingly it is unlikely that there is any detectable difference in relation to 
T1D, which was further supported by our finding that no difference were seen even in the 
highest 25(OH)D concentration quartile where the median levels were very close to normal. 
Cord serum 25(OH)D concentrations may have a long-term influence on later health and 
associations have been reported with childhood metabolic profiles (31) and early childhood 
growth together with neural development (32). Maternal vitamin D levels have been shown to 
have more influence on cord serum 25(OH)D than the genetic factors of the offspring (16). 
As we showed here, maternal intake of vitamin D during pregnancy has a clear impact on 
cord serum 25(OH)D levels and quite surprisingly, vitamin D intake was not associated with 
energy intake or maternal age. The factors behind the higher 25(OH)D concentrations in the 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2018-02094/5289723 by U
niversity of H
elsinki, Viikki Science Library user on 23 January 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2018-02094 
 
 
8
cord serum samples of older mothers, which has been reported also in other studies (33,34),  
would require further research.         
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Figure 1: Monthly distribution of median 25(OH) D concentrations in cord serum samples 
were similar in the four groups. There were no statistically significant differences between 
T1D+ (solid black line) and T1D- (dashed black line) children (P=0.39) or between IA+ 
(dashed grey line) and IA- (short-dashed grey line) children (P=0.63). Serum 25(OH)D 
concentrations were statistically significantly affected by month of birth (P=0.002). 
Table 1: General characteristics of the study population, values are median (IQR). The value 
of P < 0.05 (two-tailed) was taken to indicate statistical significance and is marked in bold. 
 T1D+N=250 T1D-N=250 IA+N=132 IA-N=132 P-value 
25(OH)D in nmol/L 30.7 (22.9- 43.3) 31.1 (24.5- 39.8) 30.7 (23.3-41.8) 31.2 (25.2-40.5) 0.70 
Weight in kg 3.59 (3.26-3.90) 3.65 (3.30-3.97) 3.64 (3.26-3.97) 3.63 (3.33-3.90) 0.76 
Height in cm 50 (49-52) 51 (49-52) 51 (49-52) 50 (49-52) 0.58 
Seroconversion age in 
years 
2.0 (1.1-4.0) N.A. 4.0 (1.8-6.2) N.A. <0.001 
Age at T1D diagnosis in 
years 
6.7 (4.0-10.1) N.A. N.A. N.A.  
Gestational age in weeks 39.9 (38.7-40.7) 40.1 (39.0-40.9) 39.9 (38.7-40.7) 40 (38.9-41) 0.32 
Age of mother in years 30.1 (26.9-33.9) 29.2 (26.4-32.7) 29.8 (26.0-34.8) 29.8 (26.8-33.7) 0.45 
Time of follow-up in 
years 
6.2 (3.4-9.3) 10.5 (6.9-14.3) 12.6 (9.1-14.8) 12.0 (8.4-14.7) <0.001 
Table 2: Subjects divided into quarters based on 25(OH)D concentration. The value of P < 
0.05 (two-tailed) was taken to indicate statistical significance and is marked in bold. 
Quarter (N) Q1 (N=191) Q2 (N=191) Q3 (N=191) Q4 (N=191) P-value 
Median 25(OH)D (range) 
in nmol/L 
20.14 (9.40-24.00) 27.75 (24.00-31.06) 34.95 (31.06-41.72) 49.27 (41.76-135.1) 
N T1D+ / T1D- / IA+ / 
IA- 
74 / 55 / 35 / 27 52 / 69 / 34 / 36 55 / 70 / 30 / 36 69 / 56 / 33 / 33 0.29 
N Turku / Oulu / Tampere 51 / 91 / 49 64 / 69 /58 74 / 62 / 55 77 / 52 / 62 0.003 
N Season (Jan-Mar)/ 
(Apr-Jun) / (Jul-Sep) / 
(Oct-Dec) 
74 / 53 / 10 / 54 65 / 54 / 22 / 50 54 / 46 / 43 / 48 17 / 29 / 112 / 33 <0.001 
N girls / boys 82 / 109 70 / 121 81 / 110 77 / 114 0.58 
N old HLA high/moderate 50 / 141 68 / 123 64 / 127 64 / 127 0.20 
N new HLA (NA/non-
incr. slight/mod/high) 
34 / 9 / 40 / 70 / 37 27 / 8 / 33 / 80 / 43 51 / 11 / 29 / 52 / 48 26 / 7 / 33 / 77 / 48 0.027 
Median ponderal index in 
kg/m3 (IQR) 
27.84 (26.31-29.60) 27.71 (26.37-29.44) 27.59 (25.88-29.11) 27.55 (25.71-29.10) 0.12 
Median weight in kg 
(IQR) 
3.61 (3.28-3.95) 3.68 (3.36-3.97) 3.63 (3.28-3.93) 3.53 (3.27-3.90) 0.28 
Median height in cm 
(IQR) 
51 (49-52) 51 (49-52) 51 (49-52) 50 (49-52) 0.77 
N mothers  
non-smoking/ smoking / 
NA  
160 / 21 / 10 163 / 15 / 10 170 / 17 / 4 162 / 14 / 15 0.70 
N of cases with IAA 
/GAD appearing first 
31 / 26 28 / 31 34 / 19 30 / 33 0.25 
N of children with  
0/1/2/3/4 autoantibodies 
81 / 2 / 20 / 28 / 55 105 / 1 / 23 / 22 / 38  106 / 2 / 16 / 26 / 40 88 / 1 / 19 / 33 / 44 0.37 
Table 3: General characteristics of the subpopulation participating in nutritional study during 
pregnancy. The value of P < 0.05 (two-tailed) was taken to indicate statistical significance. 
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Group T1D+N=121 T1D-N=119 IA+N=63 IA-N=60 P-value 
N Oulu/Tampere 51 / 70 49 / 70 35 / 28 33 / 27 0.11 
N mother of a boy/girl 54 / 67 52 / 67 26 / 37 24 / 36 0.94 
Age of mother in years 
(median [IQR]) 
29.6 (26.5-34.2) 29.3 (26.7-33.2) 28.4 (25.2-32.7) 29.1 (26.8-33.0) 0.76 
Birth weight in kg 
(median [IQR]) 
3.5 (3.2-3.9) 3.7 (3.3-4.0) 3.6 (3.2-3.9) 3.6 (3.3-4.0) 0.56 
Birth height in m 
(median [IQR])  
0.50 (0.49-0.52) 0.51 (0.49-0.52) 0.51 (0.49-0.52) 0.50 (0.49-0.52) 0.81 
Ponderal index in kg/m3 
(median [IQR]) 
27.9 (26.4-29.5) 28.3 (26.3-29.5) 27.7 (26.1-28.7) 27.7 (26.4-29.6) 0.34 
Energy intake per day 
in kJ (median [IQR]) 
10876 (8842-13062) 10876 (9808-
13094) 
11364 (9666-12976) 11354 (9364-
12656) 
0.38 
Vitamin D intake per 
day from food in µg 
(median [IQR]) 
4.92 (3.47-6.69) 5.24 (3.75-7.74) 5.22 (3.45-7.01) 4.71 (2.94-6.51) 0.21 
Vitamin D intake per 
day from supplements 
in µg (median [IQR]) 
0 (0-2.11) 0 (0-1.5) 0 (0-2.39) 0 (0-0.76) 0.85 
Total vitamin D intake 
per day  in µg (median 
[IQR]) 
5.84 (3.91-8.96) 6.53 (4.06-9.84) 5.96 (4.09-9.29) 6.53 (4.06-9.84) 0.38 
Table 4: Nutritional data during the eighth month of pregnancy when divided into the same 
25(OH)D concentration quarters as the entire data set in Table 2. The value of P < 0.05 (two-
tailed) was taken to indicate statistical significance and is marked in bold. 
Quarter Original median 
25(OH)D (range) in 
nmol/L 
Q1 20.14 (9.40-
24.00) 
Q2 27.75 (24.00-
31.06) 
Q3 34.95 (31.06-
41.72) 
Q4 49.27 (41.76-
135.1) 
P-value 
Median 25(OH)D 
(range) in nmol/L of 
subcohort 
20.53 (9.40-24.00) 27.76 (24.00-31.06)  35.12 (31.11-41.72) 50.06 (41.76-105.1)  
N of children with 
nutritional data during 
pregnancy 
103 87 88 85 0.23 
Vitamin D intake from 
food per day in µg 
(median [IQR]) 
4.25 (2.95-5.86) 4.83 (3.54-6.84) 4.94 (3.58-6.95) 6.43 (4.29-9.25) 0.007 
Vitamin D intake from 
supplements per day in 
µg (median [IQR]) 
0 (0-0) 0 (0-1.50) 0 (0-3.99) 0 (0-2.97) <0.001 
Total vitamin D intake 
per day in µg (median 
[IQR]) 
4.76 (3.15-6.10) 5.91 (3.72-8.62) 7.26 (4.16-9.17) 8.43 (5.09-12.00) <0.001 
Energy intake per day in 
kJ (median [IQR]) 
11107 (9424-12976) 11051 (8922-13789) 11220 (8905-13298) 11617 (10000-
13490) 
0.71 
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